Biotechnology Daily
more-
As esophageal cancer incidence rises, trials and potential treatments burgeon: Novotech report
While the global incidence of esophageal cancer has increased, so too have the numbers of…
Market Watch
more-
UFP Technologies Shares Rise After 3Q Jump in Medical Market Sales
UFP Technologies shares were up 24% to $344.99 after the company reported third-quarter earnings and…
Wall Street Rallies on Election Day as Economy Remains Solid
Many Retailers Offer ‘Returnless Refunds.’ Just Don’t Expect Them to Talk Much About It
Wall Street Drifts Ahead of Election Day and a Manic Week for Markets
TGI Fridays Files for Bankruptcy Protection as Sit-Down Restaurant Struggles Continue
Bio Business News
more
OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs
OS Therapies will list on the NYSE American stock exchange…
IRA drug price reductions won’t hurt biotech innovation, analyses find
Since its passage in August 2022, the Inflation Reduction Act…
Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential
We already know that Takeda is hoping to find a…
World News
more
Stocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
As esophageal cancer incidence rises, trials and potential treatments burgeon: Novotech report
The FDA is hiring. Wanted: One (1) CDRH Director
Stryker tucks in breast tumor marker maker amid ‘bullish’ M&A pipeline
AC Immune claims new class of Alzheimer’s-focused ADC has ‘landmark’ CNS potential
OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs
IRA drug price reductions won’t hurt biotech innovation, analyses find
Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential
Ideaya, eyeing drug combos, bags option on Biocytogen bispecific ADC in $400M deal
UFP Technologies Shares Rise After 3Q Jump in Medical Market Sales
Wall Street Rallies on Election Day as Economy Remains Solid